Clinical Trial

Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 27, 2026 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy. The primary objective of this study is to evaluate the incidence, type, and severity of infectious complications in hematologic patients undergoing treatment with bispecific antibodies. Secondary objectives include identifying risk factors associated with infection, comparing infectious outcomes across different hematologic malignancies and BsAb types, and assessing the impact of infections on overall treatment outcomes.
Trial Details
NCT Number NCT07609576
Lead Sponsor Infanta Leonor University Hospital
Conditions Lymphoma Neoplasms, Myeloma Multiple, Severe Infection, CMV Reactivation, Biespecific Treatment, Biespecific
Enrollment 350 participants
Start Date 2026-05-14
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-27